Request Demo

Last update 27 Feb 2026

Metoprolol Succinate

Last update 27 Feb 2026

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Metoprolol succinate (USP), H 93/26 SUCCINATE, Kapspargo sprinkle

+ [4]

Target

β1-adrenergic receptor

Action

antagonists

Mechanism

β1-adrenergic receptor antagonists(Beta-1 adrenergic receptor antagonists)

Therapeutic Areas

Nervous System DiseasesCardiovascular DiseasesEndocrinology and Metabolic Disease+ [1]

Active Indication

Arrhythmias, CardiacMigraine DisordersMyocardial Infarction+ [6]

Inactive Indication

Acute myocardial infarctionEssential HypertensionFasting+ [2]

Originator Organization

AstraZeneca PLC

Active Organization

AstraZeneca Pharmaceuticals Co. Ltd.

Libbs Farmacêutica Ltda.

Melinta Therapeutics, Inc.

+ [2]

Inactive Organization

AstraZeneca PLC

Ipca Laboratories Ltd.

License Organization

Melinta Therapeutics, Inc.

CorMedix, Inc.

New American Therapeutics, Inc.

+ [3]

Drug Highest PhaseApproved

First Approval Date

United States (10 Jan 1992),

Angina PectorisHypertension

Regulation-

Structure/Sequence

Molecular FormulaC19H31NO7

InChIKeyZBOQQGAVXCUYJM-UHFFFAOYSA-N

CAS Registry98418-47-4

115

Clinical Trials associated with Metoprolol Succinate

NCT04914234

/ RecruitingPhase 4IIT

Premedication With Atenolol Versus Metoprolol for Controlled Hypotensive Anesthesia During Nasal Surgeries. A Randomized Clinical Trial

Objectives: To compare the safety and efficacy of oral atenolol versus oral metoprolol as a premedication for controlled hypotensive anesthesia during nasal surgeries.
Background: Mucosal bleeding is the most frequent complication with nasal surgeries, as it interferes with the optimal visualization of the intranasal anatomy, increases operation time, and consequently increases blood loss. There are several pharmacological and non-pharmacological techniques for the appropriate control of intraoperative bleeding.
Patients and Methods: This was a prospective, randomized, double-blind, phase four, comparative clinical trial; carried out on 60 patients, who were candidates for nasal surgeries under general anesthesia at our hospital. Patients were randomly allocated into two equal groups; group A, received oral atenolol, and group M, received oral metoprolol.

Start Date01 Aug 2025

Sponsor / Collaborator-

NCT06967194

/ RecruitingNot ApplicableIIT

Early Beta-Blocker Administration in Patients With ST Segment Elevation Myocardial Infraction and SCAI B Status

This study is looking at how a medication called beta-blockers (metoprolol) affects patients with a heart attack (STEMI) who are in the cardiac intensive care unit.
When patients are admitted to the unit, they will be randomly placed in one of two groups. One group will get the metoprolol medication, and the other will receive a placebo (a harmless pill that looks like the real medication). All other treatments will be the same for both groups.
During the study, which is 72 hours long, patients will be monitored for blood pressure, heart rate, and lactate levels alterations.
The main goal is to see if the medication helps improve patients condition or prevent it from getting worse. patients safety is a top priority, and if needed, the doctors can stop the study at any time if there are concerns.

Start Date21 May 2025

Sponsor / Collaborator

Tel Aviv Sourasky Medical Center

ITMCTR2024000536

/ SuspendedPhase 4

A multicenter randomized controlled study on the efficacy and safety of Qidong Yixin granules combined with metoprolol succinate sustained-release tablets in the treatment of ventricular premature beats (Qi Yin deficiency syndrome)

Start Date01 Nov 2024

Sponsor / Collaborator

Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd.

100 Clinical Results associated with Metoprolol Succinate

100 Translational Medicine associated with Metoprolol Succinate

100 Patents (Medical) associated with Metoprolol Succinate

397

Literatures (Medical) associated with Metoprolol Succinate

01 Feb 2026·DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY

Greenness assessment and stability-indicating HPTLC method for the concurrent analysis of empagliflozin and metoprolol succinate in a novel combined oral formulation

Article

Author: Ninama, Heena ; Koradia, Shaileshkumar K.

BACKGROUND:

Empagliflozin a sodium-glucose co-transporter 2 inhibitor, and Metoprolol succinate, a cardioselective β1-blocker, are co-formulated in a novel bilayer tablet currently under clinical evaluation. Reliable stability-indicating methods are required for simultaneous quantification of these drugs and to ensure environmental sustainability of pharmaceutical analysis.

OBJECTIVE:

To develop and validate a stability-indicating HPTLC method for concurrent quantification of EMP and METO in a novel combined oral formulation, in compliance with ICH Q2(R2) guidelines.

METHODS:

Chromatographic separation was achieved on HPTLC silica gel 60 F₂₅₄ plates using chloroform: methanol: toluene (3.0:2.5:4.5, v/v/v) as mobile phase. Detection was carried out at 222 nm. The method was validated for specificity, linearity, accuracy, precision, robustness, and sensitivity. Stressed degradation studies under acid, base, oxidative, thermal, and photolytic conditions were performed.

RESULTS:

EMP and METO exhibited Rf values of 0.54 and 0.26, respectively. Linearity was observed over 100-600 ng/band for EMP (r² = 0.9987) and 500-3000 ng/band for METO (r² = 0.9998). Recovery ranged from 99.54-101.21% (EMP) and 98.23-100.73% (METO). LOD/LOQ values were 24.67/74.76 ng/band (EMP) and 45.29/137.25 ng/band (METO). The method demonstrated precision in both intraday (EMP-8738.68 ± 80.86 and METO- 4510.93 ± 27.61) and interday (EMP-8744.97 ± 131.91 and MET0-4492.87 ± 32.53) analyses and repeatability, with the %RSD of the peak area remaining below 2%. The stressed degradation conditions were optimized to induce degradation ranging from 5% to 20%.

CONCLUSION:

The validated HPTLC method is precise, accurate, and stability-indicating, making it suitable for routine quality control and stability testing of EMP-METO bilayer tablets.

01 Jan 2026·EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES

Development of a 3D printed multiple unit particle system (MUPS) containing metoprolol succinate

Article

Author: Oldfield, Lee Roy ; Seidlitz, Anne ; Fischer, Björn ; Auel, Tobias

This study presents the development and characterisation of dual extrusion 3D printed multiple unit particle system (MUPS) tablets incorporating metoprolol succinate. Pharmaceutical-grade filaments were prepared via hot-melt extrusion, comprising a drug loaded sustained release formulation of Eudragit® RL PO, and a rapidly disintegrating tablet shell formulation based on Kollicoat® IR. The use of fused filament fabrication enabled the integration of drug-loaded cylindrical particles within the tablet shell. Comprehensive morphological and structural analyses, including scanning electron microscopy, X-ray micro-computed tomography, and digital microscopy, confirmed uniform particle geometry and distribution. The manufactured tablets met European Pharmacopoeia (Ph. Eur.) specifications for mass uniformity. Disintegration testing demonstrated complete disintegration of the tablet shell within 15 min. X-ray powder diffraction indicated the active pharmaceutical ingredient (API) was present in an amorphous state post-processing. High-performance liquid chromatography analysis revealed thermal degradation during 3D printing, with a reduction in API content from 97.8 % in the extruded filament to 65.9 % in the printed MUPS tablets. A linear correlation between the number of printed particle layers and the final drug content was shown, supporting the concept of dose individualisation. In vitro dissolution testing showed that 80 % of the incorporated API was released within 105 to 150 min. The findings confirm the feasibility of producing API-3D-MUPS tablets using pharmaceutical-grade materials, while also identifying critical product defects, formulation and process parameters such as thermal instability of the API or particle agglomeration - that require further optimisation of formulation and process parameters to enable broader application in personalised drug delivery.

01 Nov 2025·JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Aficamten in Obstructive Hypertrophic Cardiomyopathy

Article

Author: Claggett, Brian L ; Costabel, Juan Pablo ; Kulac, Ian J ; de Barros Correia, Edileide ; Bilen, Ozlem ; Schulze, P Christian ; Wohltman, Amy ; Solomon, Scott D ; Peña-Peña, Maria Luisa ; Reant, Patricia ; Lakdawala, Neal K ; Garcia-Pavia, Pablo ; Heitner, Stephen B ; Lewis, Gregory D ; Kupfer, Stuart ; Mann, Amy ; Malik, Fady I ; Poulsen, Steen H ; Masri, Ahmad ; Hegde, Sheila M ; Burroughs, Melissa ; Sohn, Regina ; Barriales-Villa, Roberto ; Fifer, Michael A ; Berhane, Indrias ; Maron, Martin S ; Nassif, Michael E ; Merkely, Bela ; Elliott, Perry ; Nair, Ajith ; Wang, Andrew ; Jacoby, Daniel L ; Dybro, Anne

BACKGROUND:

For >60 years, beta-blockers have been first-line therapy for symptomatic obstructive hypertrophic cardiomyopathy (oHCM), although limited data support this recommendation. The MAPLE-HCM trial showed greater improvement in exercise capacity and secondary endpoints for aficamten monotherapy vs metoprolol monotherapy.

OBJECTIVES:

The purpose of this study was to evaluate the effects of aficamten vs metoprolol across multiple clinically relevant and patient-centric measures of disease burden in oHCM.

METHODS:

Patients with oHCM and left ventricular outflow tract gradient (LVOT-G) ≥30 mm Hg at rest and/or ≥50 mm Hg with Valsalva were randomly assigned to aficamten (n = 88) or metoprolol (n = 87). Dose titration was based on vital signs and echocardiograms. Assessment of clinical response by treatment arm was based on improvement in multiple parameters reflecting oHCM disease burden: LVOT-G <30 mm Hg at rest and <50 mm Hg with Valsalva; ≥1 class improvement in NYHA functional class and/or ≥10-point improvement in Kansas City Cardiomyopathy Questionnaire-Clinical Summary Score (KCCQ-CSS); ≥50% reduction in N-terminal pro-B-type natriuretic peptide; ≥1.0 mL/kg/min increase in peak oxygen consumption (pVO₂); and ≥10% reduction in left atrial volume index. Clinical response was classified by number of efficacy outcomes achieved: nonresponder (none), limited (1 or 2), positive (3 or 4), or complete (all 5).

RESULTS:

Baseline characteristics were similar for both treatment groups. For the overall cohort, mean age was 58 ± 13.2 years; 73 (42%) were women, 103 (70%) were in NYHA functional class II and 52 (30%) in class III, mean pVO₂ was 19.9 ± 5.1 mL/kg/min, and mean KCCQ-CSS score was 66 ± 16. At 24 weeks, aficamten treatment was associated with greater benefits in all efficacy outcome measures, with numbers needed to treat ranging from 1.5 to 5.0 relative to metoprolol treatment. Patients treated with aficamten were more likely to be either positive or complete responders compared with patients treated with metoprolol (78% vs 3%, respectively; P < 0.001).

CONCLUSIONS:

In patients with symptomatic oHCM, aficamten monotherapy led to superior and rapid treatment benefits across several clinically relevant outcome measures of disease burden compared with metoprolol. These observations support the emerging role of aficamten as monotherapy for oHCM. (Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Metoprolol Succinate in Adults With Symptomatic oHCM [MAPLE-HCM]; NCT05767346).

News (Medical) associated with Metoprolol Succinate

02 Feb 2026

·cormedix.com

CORMEDIX THERAPEUTICS ANNOUNCES SHARE REPURCHASE PROGRAM

Berkeley Heights, NJ – February 2, 2026 – CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced its Board of Directors has approved a share repurchase program, which authorizes the Company to repurchase up to $75 million of the Company’s outstanding common stock. The repurchase program is authorized through December 31, 2027. “With a strong balance sheet, solid operating performance, and expected ongoing cash flow generation, we believe we are well positioned to execute this share repurchase program while continuing to advance our growth strategy,” said Joseph Todisco, Chairman & CEO of CorMedix Therapeutics. “The program provides a disciplined way to return value to shareholders while preserving the financial flexibility to invest in our business, including potential inorganic opportunities. We remain confident in our long-term outlook and in the potential of our late-stage clinical programs to deliver meaningful benefits for patients.” CorMedix expects to begin repurchasing shares as early as Q1 2026 and had approximately $150 million in cash and cash equivalents, and 79.3 million common shares outstanding as of December 31, 2025. Repurchases may be made at management’s discretion from time to time in privately negotiated transactions, through block trades, pursuant to open market purchases or pursuant to trading plans as permitted under applicable securities laws. In addition, any repurchases under the authorization will be subject to prevailing market conditions, liquidity and cash flow considerations, applicable securities laws and regulations, and other factors. The share repurchase program does not require CorMedix Therapeutics to acquire any amount of shares, and may be suspended or discontinued at any time. About CorMedix CorMedix Therapeutics is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. CorMedix is commercializing DefenCath® (taurolidine and heparin) for the prevention of catheter-related bloodstream infections in adult patients undergoing hemodialysis via a central venous catheter. Following its August 2025 acquisition of Melinta Therapeutics LLC, CorMedix is also commercializing a portfolio of anti-infective products, including MINOCIN® (minocycline) for Injection, REZZAYO® (rezafungin for injection), VABOMERE® (meropenem and vaborbactam), ORBACTIV™ (oritavancin), BAXDELA® (delafloxacin), and KIMYRSA® (oritavancin), as well as TOPROL-XL® (metoprolol succinate). CorMedix has ongoing clinical studies for DefenCath in Total Parenteral Nutrition (TPN) and Pediatric Hemodialysis populations and also intends to develop DefenCath as a catheter lock solution for use in other patient populations. REZZAYO is currently approved for the treatment of candidemia and invasive candidiasis in adults, with an ongoing Phase III study for the prophylaxis of IFD in adult patients undergoing allogeneic BMT. Topline results of the Phase III study for REZZAYO are expected in Q2 2026. For more information visit: www.cormedix.com or www.melinta.com. Forward-Looking Statements This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are subject to risks and uncertainties. Forward-looking statements are often identified by the use of words such as, but not limited to, “anticipate,” “believe,” “can,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “project,” “seek,” “should,” “target,” “will,” “would,” and similar expressions or variations intended to identify forward-looking statements. All statements, other than statements of historical facts, regarding management’s expectations, beliefs, goals, plans or CorMedix’s prospects should be considered forward-looking statements including, but not limited to statements regarding financial and operating results, cash flow, shareholder return, outlook of the business, expectations regarding timing, execution and impact of the share repurchase program, expectations and timing regarding clinical studies and development and expectations of CorMedix’s product pipeline, expectations regarding implementation and perceived benefits of CorMedix’s products. Readers are cautioned that actual results may differ materially from projections or estimates due to a variety of important factors, and readers are directed to the Risk Factors identified in CorMedix’s filings with the SEC, including its most recent Annual Report on Form 10-K, copies of which are available free of charge at the SEC’s website at www.sec.gov or upon request from CorMedix. CorMedix may not actually achieve the goals or plans described in its forward-looking statements, and such forward-looking statements speak only as of the date of this press release. Investors should not place undue reliance on these statements. CorMedix assumes no obligation and does not intend to update these forward-looking statements, except as required by law. Investor Contact: Dan Ferry Managing Director LifeSci Advisors daniel@lifesciadvisors.com (617) 430-7576

Phase 3AcquisitionDrug Approval

02 Feb 2026

·www.biospace.com

CorMedix Therapeutics Announces Share Repurchase Program

BERKELEY HEIGHTS, N.J., Feb. 02, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced its Board of Directors has approved a share repurchase program, which authorizes the Company to repurchase up to $75 million of the Company’s outstanding common stock. The repurchase program is authorized through December 31, 2027. “With a strong balance sheet, solid operating performance, and expected ongoing cash flow generation, we believe we are well positioned to execute this share repurchase program while continuing to advance our growth strategy,” said Joseph Todisco, Chairman & CEO of CorMedix Therapeutics. “The program provides a disciplined way to return value to shareholders while preserving the financial flexibility to invest in our business, including potential inorganic opportunities. We remain confident in our long-term outlook and in the potential of our late-stage clinical programs to deliver meaningful benefits for patients.” CorMedix expects to begin repurchasing shares as early as Q1 2026 and had approximately $150 million in cash and cash equivalents, and 79.3 million common shares outstanding as of December 31, 2025. Repurchases may be made at management’s discretion from time to time in privately negotiated transactions, through block trades, pursuant to open market purchases or pursuant to trading plans as permitted under applicable securities laws. In addition, any repurchases under the authorization will be subject to prevailing market conditions, liquidity and cash flow considerations, applicable securities laws and regulations, and other factors. The share repurchase program does not require CorMedix Therapeutics to acquire any amount of shares, and may be suspended or discontinued at any time. About CorMedix CorMedix Therapeutics is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. CorMedix is commercializing DefenCath ® (taurolidine and heparin) for the prevention of catheter-related bloodstream infections in adult patients undergoing hemodialysis via a central venous catheter. Following its August 2025 acquisition of Melinta Therapeutics LLC, CorMedix is also commercializing a portfolio of anti-infective products, including MINOCIN ® (minocycline) for Injection, REZZAYO ® (rezafungin for injection), VABOMERE ® (meropenem and vaborbactam), ORBACTIV ™ (oritavancin), BAXDELA ® (delafloxacin), and KIMYRSA ® (oritavancin), as well as TOPROL-XL ® (metoprolol succinate). CorMedix has ongoing clinical studies for DefenCath in Total Parenteral Nutrition (TPN) and Pediatric Hemodialysis populations and also intends to develop DefenCath as a catheter lock solution for use in other patient populations. REZZAYO is currently approved for the treatment of candidemia and invasive candidiasis in adults, with an ongoing Phase III study for the prophylaxis of IFD in adult patients undergoing allogeneic BMT. Topline results of the Phase III study for REZZAYO are expected in Q2 2026. For more information visit: or . Forward-Looking Statements This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are subject to risks and uncertainties. Forward-looking statements are often identified by the use of words such as, but not limited to, “anticipate,” “believe,” “can,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “project,” “seek,” “should,” “target,” “will,” “would,” and similar expressions or variations intended to identify forward-looking statements. All statements, other than statements of historical facts, regarding management’s expectations, beliefs, goals, plans or CorMedix’s prospects should be considered forward-looking statements including, but not limited to statements regarding financial and operating results, cash flow, shareholder return, outlook of the business, expectations regarding timing, execution and impact of the share repurchase program, expectations and timing regarding clinical studies and development and expectations of CorMedix’s product pipeline, expectations regarding implementation and perceived benefits of CorMedix’s products. Readers are cautioned that actual results may differ materially from projections or estimates due to a variety of important factors, and readers are directed to the Risk Factors identified in CorMedix’s filings with the SEC, including its most recent Annual Report on Form 10-K, copies of which are available free of charge at the SEC’s website at or upon request from CorMedix. CorMedix may not actually achieve the goals or plans described in its forward-looking statements, and such forward-looking statements speak only as of the date of this press release. Investors should not place undue reliance on these statements. CorMedix assumes no obligation and does not intend to update these forward-looking statements, except as required by law. Investor Contact: Dan Ferry Managing Director LifeSci Advisors daniel@lifesciadvisors.com (617) 430-7576

Phase 3AcquisitionDrug Approval

08 Jan 2026

·www.biospace.com

CorMedix Therapeutics Announces Preliminary Fourth Quarter and Full Year 2025 Results and Provides Business Updates

‒ Q4 2025 Unaudited Net Revenue of Approximately $127 million ‒ ‒ FY 2025 Unaudited Pro Forma Net Revenue of Approximately $400 million ‒ ‒ Expects Q4 Adjusted EBITDA of Between $77 million and $81 million ‒ ‒ Unaudited Cash and Short-term Investments of Approximately $148 million ‒ BERKELEY HEIGHTS, N.J., Jan. 08, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announces its preliminary unaudited fourth quarter 2025 and full-year 2025 results, and provides guidance and an update on its business. These include the following key updates: CorMedix announces preliminary, unaudited financial results for Q4 and FY 2025, including net revenue of approximately $127 million and $310 million, for Q4 2025 and FY 2025, respectively, FY 2025 Pro Forma net revenue (1) of approximately $400 million, and Q4 2025 adjusted EBITDA ( 2 ) in the range of $77 million to $81 million. The Company reports preliminary unaudited cash and short-term investments, as of December 31, 2025, of approximately $148 million. CorMedix expects clinical data from the Phase 3 ReSPECT study of REZZAYO® (rezafungin for injection) in the prophylaxis of invasive fungal infection in adult patients undergoing allogeneic blood and marrow transplant in Q2 2026. In addition, the ongoing Phase 3 study of taurolidine/heparin catheter lock solution in TPN patients continues to enroll patients with targeted completion in early 2027. The Company continues to see strong utilization and patient growth for DefenCath® (taurolidine and heparin) by its outpatient dialysis organization customers. On July 1, 2026, DefenCath’s TDAPA reimbursement transitions into a post-TDAPA Add-On Adjustment, the calculation of which is determined by CMS. As a result of the methodology utilized by CMS, the level of reimbursement provided to institutions treating dialysis patients will significantly decline, and as a result, CorMedix expects a corresponding reduction to its net pricing for DefenCath in Q3 and Q4 of 2026. If CMS utilizes the same methodology to calculate the 2027 post-TDAPA Add-On Adjustment, which will be effective on January 1, 2027, CorMedix estimates the value of the Add-On Adjustment will be 3x – 5x higher than that granted for Q3 and Q4 of 2026, which the Company expects would result in higher DefenCath sales prices in 2027 relative to H2 2026. CorMedix is introducing FY 2026 Revenue guidance of $300 million to $320 million, which includes $150 million to $170 million for DefenCath. 2026 DefenCath revenue guidance is heavily weighted toward H1 2026 and assumes modest utilization growth, which the Company expects will offset some of the price erosion over the course of the year. Based on the assumption of a higher net selling price in 2027 relative to H2 2026, the Company currently estimates full-year 2027 DefenCath sales in the range of $100 million to $140 million. DefenCath guidance for 2026 and 2027 assumes the maintenance of its current outpatient dialysis utilization run-rate with existing customers, and excludes any potential upside from new outpatient dialysis customers, increased utilization due to anticipated Medicare Advantage contracting, or any change in reimbursement due to pending TDAPA legislation. In addition, management has operationalized synergies of approximately $35 million, on a full-year run rate basis, related to the acquisition of Melinta and is now focused on driving growth strategies for the business. The Company is estimating FY 2026 operating expenses of $145 million to $160 million, excluding non-cash items and one-time expenses, with the upper end of the spending range contingent upon positive Phase 3 data related to the ReSPECT study and a potential acceleration of enrollment in the DefenCath TPN study. Based on these estimates, CorMedix estimates FY 2026 Adjusted EBITDA in the range of $100 million to $125 million. CorMedix is excited to announce that it will hold an Analyst Day on February 10, 2026, during which it will provide significant background on the medical need and the market potential for its key pipeline assets of REZZAYO in prophylaxis and DefenCath in TPN, as well as insights on the future strategic direction for the business. Details will be forthcoming. Joseph Todisco, CorMedix Therapeutics CEO, commented, “I’m proud to announce our preliminary Q4 and FY 2025 results today, including surpassing our guidance for 2025. 2025 was a transformational year for CorMedix, as we evolved beyond a single-product company to an organization with multiple growth drivers and pipeline assets. We closed 2025 in a strong cash position, which we expect to further bolster over the coming year, providing the Company with financial flexibility to drive value for shareholders. With our new leadership team in place and multiple near-term pipeline catalysts, I am excited about the long-term potential for CorMedix Therapeutics.” The preliminary financial information presented in this press release is based on CorMedix’s current expectations and may be adjusted as a result of, among other things, the completion of our internal review process and the completion of customary annual audit procedures. (1) FY 2025 Unaudited Pro Forma Net Revenue was prepared by combining the estimated financial results and for CorMedix and Melinta for the full fiscal year ended December 31, 2025, without further adjustment, as if the transaction had closed on January 1, 2025. (2) Adjusted EBITDA is a non-GAAP financial measure and excludes non-cash items such as depreciation, amortization and stock-based compensation, and certain non-recurring items. The Company expects to provide a reconciliation of Adjusted EBITDA to the most comparable GAAP measure in its earnings release relating to the fourth quarter and full year 2025 financial results. Such reconciliation is not included in this release because CorMedix is currently finalizing certain amounts that would be required to be included in the U.S. GAAP measure or the individual adjustments for such reconciliation. About CorMedix CorMedix Therapeutics is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. CorMedix is commercializing DefenCath ® (taurolidine and heparin) for the prevention of catheter-related bloodstream infections in adult patients undergoing hemodialysis via a central venous catheter. Following its August 2025 acquisition of Melinta Therapeutics LLC, CorMedix is also commercializing a portfolio of anti-infective products, including MINOCIN ® (minocycline) for Injection, REZZAYO ® (rezafungin), VABOMERE ® (meropenem and vaborbactam), ORBACTIV ™ (oritavancin), BAXDELA ® (delafloxacin), and KIMYRSA ® (oritavancin), as well as TOPROL-XL ® (metoprolol succinate). CorMedix has ongoing clinical studies for DefenCath in Total Parenteral Nutrition (TPN) and Pediatric Hemodialysis populations and also intends to develop DefenCath as a catheter lock solution for use in other patient populations. REZZAYO is currently approved for the treatment of candidemia and invasive candidiasis in adults, with an ongoing Phase III study for the prophylaxis of IFD in adult patients undergoing allogeneic BMT. Topline results of the Phase III study for REZZAYO are expected in Q2 2026. For more information visit: or . Forward-Looking Statements This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act, and Section 21E of the Exchange, as amended (the “Exchange Act”), that are subject to risks and uncertainties. Forward-looking statements are often identified by the use of words such as, but not limited to, “anticipate,” “believe,” “can,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “will,” “plan,” “project,” “seek,” “should,” “target,” “will,” “would,” and similar expressions or variations intended to identify forward-looking statements. All statements, other than statements of historical facts, regarding management’s expectations, beliefs, goals, plans or CorMedix’s prospects should be considered forward-looking statements including, but not limited to statements regarding financial guidance, sales, revenue and operating expense estimates, expectations regarding product utilization, product reimbursement rates, synergy estimates and timing, expectations and timing regarding clinical studies and development and expectations of CorMedix’s product pipeline, results of the real-world study, expectations regarding implementation and perceived benefits of CorMedix’s products. Readers are cautioned that actual results may differ materially from projections or estimates due to a variety of important factors, and readers are directed to the Risk Factors identified in CorMedix’s filings with the SEC, including its most recent Annual Report on Form 10-K, copies of which are available free of charge at the SEC’s website at or upon request from CorMedix. CorMedix may not actually achieve the goals or plans described in its forward-looking statements, and such forward-looking statements speak only as of the date of this press release. Investors should not place undue reliance on these statements. CorMedix assumes no obligation and does not intend to update these forward-looking statements, except as required by law. Investor Contact: Dan Ferry Managing Director LifeSci Advisors daniel@lifesciadvisors.com (617) 430-7576

Phase 3AcquisitionDrug ApprovalFinancial Statement

100 Deals associated with Metoprolol Succinate

External Link

KEGG	Wiki	ATC	Drug Bank
D00635	Metoprolol Succinate	C07AB02	DB00264

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Migraine Disorders	Brazil	Libbs Farmacêutica Ltda.	23 Dec 2019
Myocardial Infarction	Brazil	Libbs Farmacêutica Ltda.	23 Dec 2019
Arrhythmias, Cardiac	Brazil	Libbs Farmacêutica Ltda.	23 Dec 2019
Chronic heart failure	Australia	AstraZeneca Pty Ltd.	28 Oct 2003
Heart Failure	United States	Melinta Therapeutics, Inc.	05 Feb 2001
Angina Pectoris	United States	Melinta Therapeutics, Inc.	10 Jan 1992
Hypertension	United States	Melinta Therapeutics, Inc.	10 Jan 1992
Hyperthyroidism	China	AstraZeneca Pharmaceuticals Co. Ltd.	-
Neurocirculatory Asthenia	China	AstraZeneca Pharmaceuticals Co. Ltd.	-

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Mitral Valve Insufficiency	Phase 3	United States	AstraZeneca PLC	01 Aug 2004
Essential Hypertension	Phase 3	-	AstraZeneca PLC	01 Jun 2003
Lecithin Cholesterol Acyltransferase Deficiency	Phase 1	India	Ipca Laboratories Ltd.	01 Apr 2013
Fasting	Phase 1	India	Ipca Laboratories Ltd.	01 Feb 2013
Acute myocardial infarction	Phase 1	-	AstraZeneca PLC	01 Feb 2000

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04434664 (BLOCK HFpEF, CTgov)	Phase 4	Heart failure with normal ejection fraction \| Hypertension	50	Amlodipine Besylate (Amlodipine Besylate)	malwditqjs(arvlngawnn) = jmeaypprkq haxjqkwrwf (ohurnhxmlb, 12.4) View more	-	30 Jan 2026
				Metoprolol Succinate (Metoprolol Succinate)	malwditqjs(arvlngawnn) = jhdoybwclz haxjqkwrwf (ohurnhxmlb, 17.2) View more
NCT03070184 (CTgov)	Phase 2	Prehypertension	80	Exercise challenge+Metoprolol Succinate ER (Black Participants)	bcioywpekr(gxejhfqgvq) = zbggqdzylh ftjkzozfhh (zylblyvdfj, fljshqkpbb - qkwxwmyetr) View more	-	27 Feb 2025
				Exercise challenge+Metoprolol Succinate ER (White Participants)	bcioywpekr(gxejhfqgvq) = kgeenfumpx ftjkzozfhh (zylblyvdfj, mlnyqttvsg - bggoimmajk) View more
NCT05096884 (PEACE, CTgov)	Early Phase 1	Dyspnea \| Post Acute COVID 19 Syndrome \| Tachycardia	14	Metoprolol Succinate	uvbzvrguoy(dnylnwmvss) = spiolwfmwr icumxwwhyo (irwobvhvyw, 76) View more	-	03 Dec 2024
NCT02293096 (CTgov)	Not Applicable	Hypertension \| Essential Hypertension	462	Metoprolol Succinate	pshxihippa = pipuqutkom aeqadepnyp (wqglgyvotq, yxzdqwjccd - tiuowajknq) View more	-	16 Sep 2021
NCT02587351 (CTgov)	Phase 3	Pulmonary Disease, Chronic Obstructive	532	Metoprolol succinate (Metoprolol Succinate)	vdwhsfjyck(sdhasxsoyr) = twqsojbbbv olnjfyeuqk (vbvloleqrv, iugutvrvix - dfibwqbpvx) View more	-	25 Jan 2021
				Placebo (Placebo)	vdwhsfjyck(sdhasxsoyr) = scevrtlbzn olnjfyeuqk (vbvloleqrv, kywhdoegaf - rvkgusvhvu) View more
NCT00995072 (CTgov)	Not Applicable	Female sexual dysfunction \| Hypertension	29	Nebivolol (Nebivolol 5 mg Daily)	peebjbewur(vigpkwcizm) = mgjsapkhhm mqtedubbxx (hjkcikapui, 9.183) View more	-	29 Mar 2019
				Metoprolol Succinate+Metoprolol (Metoprolol Succinate 100 mg Daily)	peebjbewur(vigpkwcizm) = qapouqufqx mqtedubbxx (hjkcikapui, 5.262) View more
NCT01395329 (NETS, CTgov)	Phase 4	Hypertension \| Prehypertension	42	FBF response to Sodium Nitroprusside+Nebivolol+ACh+BQ-788+BQ-123 (Nebivolol)	stlbwhbnyp(druarylteu) = qdlieotunw pcsyczrczt (gvequtvyso, xlhrxyumev - bawkpfgbmz) View more	-	06 Dec 2018
				FBF response to Sodium Nitroprusside+Metoprolol+ACh+BQ-788+BQ-123 (Metoprolol)	stlbwhbnyp(druarylteu) = pjcyidfsuh pcsyczrczt (gvequtvyso, ntaiamhygo - rxyxjdywji) View more
NCT01501929 (CTgov)	Phase 4	Hypertension	32	Microvascular perfusion assessment using Definity+Nebivolol+Metoprolol succinate (Initial Treatment With Metoprolol)	nydfpvedkr(stamoydnpb) = vmjeqzkwwj ucpdpsdcbd (zeeougiwbl, ykrtvjcaaf - akliikoqca) View more	-	06 Nov 2018
				Microvascular perfusion assessment using Definity+Nebivolol+Metoprolol succinate (Initial Treatment With Nebivolol)	nydfpvedkr(stamoydnpb) = bhmwpbtqui ucpdpsdcbd (zeeougiwbl, vwkxycxhtk - xqfwauqroh) View more
NCT00999102 (CTgov)	Phase 4	Fatigue \| Hypertension	37	Nebivolol (Nebivolol 5 mg for 4 Weeks)	nyvghatnco(fpihrgjgnh) = kkjbkrefzb dmqkwvpjvc (vsbnlzcenk, 11.2) View more	-	19 Oct 2018
				Metoprolol (Metoprolol 50 mg for 4 Weeks)	nyvghatnco(fpihrgjgnh) = qsmjjjfguj dmqkwvpjvc (vsbnlzcenk, 11.2) View more
NCT00756236 (CTgov)	Not Applicable	Myocardial Ischemia	60	Metoprolol (M-Group)	qrgmagalpn(bkojjdnrfb) = grhnnyrqew htbnlbjhky (pykfbttpos, 0.38) View more	-	28 Jun 2017
				Esmolol (E-Group)	qrgmagalpn(bkojjdnrfb) = simvpioskq htbnlbjhky (pykfbttpos, 0.29) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Metoprolol Succinate

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation